Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 2/20 | 0.35 |
| ▸ | ESR1 | P03372 | 2/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31566357 | 1.00 | CYP3A4 (0.42) | CYP3A4TDP1CYP1A2CYP2A6DRD1 | |
| SCHEMBL10888841 | 0.93 | CYP3A4 (0.37) | CYP3A4TDP1CYP1A2CYP2A6DRD1 | |
| SCHEMBL14513896 | 0.83 | CYP3A4 (0.38) | CYP3A4TDP1CYP1A2CYP2A6DRD1 | |
| SCHEMBL6408114 | 0.83 | RAPGEF4 (0.33) | TSHR | |
| SCHEMBL1043807 | 0.81 | CYP3A4 (0.39) | CYP3A4TDP1DRD1ESR1ESR2 | |
| SCHEMBL19009982 | 0.78 | ALDH1A1 (0.39) | CYP3A4TDP1DRD1TSHR | |
| SCHEMBL301644 | 0.78 | TDP1 (0.37) | CYP3A4TDP1DRD1ESR1ESR2 | |
| SCHEMBL31566363 | 0.78 | TDP1 (0.37) | CYP3A4TDP1DRD1ESR1ESR2 | |
| SCHEMBL12592439 | 0.78 | TDP1 (0.44) | CYP3A4TDP1CYP2A6DRD1ESR1 | |
| SCHEMBL11373195 | 0.78 | TDP1 (0.44) | CYP3A4TDP1CYP1A2CYP2A6DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1840116-B1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE BETA-HYDROXY-ALPHA-AMINOCARBOXYLIC ACID DERIVATIVE | NISSAN CHEMICAL IND LTD (JP) | 2012-10-03 | — | — | EP | claimed |
| US-7781609-B2 | Process for producing optically active β-hydroxy-α-aminocarboxylic acid derivative | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-08-24 | — | — | US | claimed |
| US-20080139825-A1 | Process For Producing Optically Active Beta-Hydroxy-Alpha-Aminocarboxylic Acid Derivative | NISSAN CHEMICAL INDUSTRIAL, LTD. (JP) | 2008-06-12 | — | — | US | claimed |
| EP-1840116-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE BETA-HYDROXY-ALPHA-AMINOCARBOXYLIC ACID DERIVATIVE | Nissan Chemical Industries, Ltd. (JP) | 2007-10-03 | — | — | EP | claimed |
| EP-1650207-B1 | Process for producing optically active 3-quinuclidinols | TAKASAGO PERFUMERY CO LTD (JP) | 2007-06-27 | — | — | EP | claimed |
| EP-0104375-A1 | Phosphorus-containing biphenyl derivatives and their use in asymmetric hydrogenation and enatioselective hydrogen shifts | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-04-04 | — | — | EP | claimed |
| US-10029968-B2 | Process for producing alcohol analogue | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2018-07-24 | — | — | US | disclosed |
| US-20170297990-A1 | PROCESS FOR PRODUCING ALCOHOL ANALOGUE | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2017-10-19 | — | — | US | disclosed |
| US-9481618-B2 | Cyclopolyarylene compound and method of manufacturing same | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2016-11-01 | — | — | US | disclosed |
| EP-2610248-B1 | METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE BY MEANS OF COUPLING METHOD USING A PALLADIUM COMPOUND | TEIJIN PHARMA LTD (JP) | 2016-06-08 | — | — | EP | disclosed |
| US-9266909-B2 | Cyclic compound containing functional group or containing no functional group, and method for producing same | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2016-02-23 | — | — | US | disclosed |
| EP-2611819-B1 | IRIDIUM COMPLEX AND METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | TAKASAGO PERFUMERY CO LTD (JP) | 2015-12-16 | — | — | EP | disclosed |
| US-20150126779-A1 | CYCLIC COMPOUND CONTAINING FUNCTIONAL GROUP OR CONTAINING NO FUNCTIONAL GROUP, AND METHOD FOR PRODUCING SAME | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2015-05-07 | — | — | US | disclosed |
| EP-0831099-A2 | Process for preparing ruthenium-phosphine complex | Takasago International Corporation (JP) | 1998-03-25 | — | — | EP | disclosed |
| US-5412109-A | Process for preparing optically active 4-methyl-2-oxetanone | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1995-05-02 | — | — | US | disclosed |
| US-5306834-A | Catalytic hydrogenation of 4-methylene-2-oxetanone | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1994-04-26 | — | — | US | disclosed |
| US-4861890-A | Isomerization | HOFFMANN-LA ROCHE INC. (US) | 1989-08-29 | — | — | US | disclosed |
| EP-0104375-B1 | PHOSPHORUS-CONTAINING BIPHENYL DERIVATIVES AND THEIR USE IN ASYMMETRIC HYDROGENATION AND ENATIOSELECTIVE HYDROGEN SHIFTS | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1986-10-15 | — | — | EP | disclosed |
| US-4556740-A | Phosphorus compounds | HOFFMANN-LA ROCHE INC. (US) | 1985-12-03 | — | — | US | disclosed |
| EP-0104375-A1 | Phosphorus-containing biphenyl derivatives and their use in asymmetric hydrogenation and enatioselective hydrogen shifts | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139825-A1 | Process For Producing Optically Active Beta-Hydroxy-Alpha-Aminocarboxylic Acid Derivative | HCAR2, HCAR1, ALDH7A1 | CYP3A4 207/4885TDP1 4714/4885CYP1A2 184/4885 |
| US-20150126779-A1 | CYCLIC COMPOUND CONTAINING FUNCTIONAL GROUP OR CONTAINING NO FUNCTIONAL GROUP, AND METHOD FOR PRODUCING SAME | CYP1B1, BCR, DDT | CYP3A4 9/4885TDP1 4445/4885CYP1A2 20/4885 |
| US-20170297990-A1 | PROCESS FOR PRODUCING ALCOHOL ANALOGUE | ADH1A, ADH1C, ADH5 | CYP3A4 523/4885TDP1 4077/4885CYP1A2 233/4885 |
| US-10029968-B2 | Process for producing alcohol analogue | ADH1A, ADH1C, ADH5 | CYP3A4 523/4885TDP1 4077/4885CYP1A2 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.